Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Ionis Pharmaceuticals (IONS) caught investor attention after announcing its investigational drug olezarsen earned Breakthrough Therapy designation from the FDA for severe hypertriglyceridemia. The move expedites potential approval and reflects strong Phase 3 trial data.
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]CNBC
- Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.MarketBeat
- Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)Business Wire
IONS
Earnings
- 10/29/25 - Beat
IONS
Sec Filings
- 2/6/26 - Form 144
- 2/4/26 - Form 4
- 2/2/26 - Form 4
- IONS's page on the SEC website